Autolus Therapeutics annual operating margin
2017
2018
2019
2023
2024
2025
Autolus Therapeutics's operating margin was −358.87% for fiscal 2025.
View full Autolus Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −358.87% | +2026.76 pp |
| 2024 | 2024-12-31 | −2,385.63% | +8197.47 pp |
| 2023 | 2023-12-31 | −10,583.10% | −5560.26 pp |
| 2019 | 2019-12-31 | −5,022.83% | −933.78 pp |
| 2018 | 2018-09-30 | −4,089.05% | −2705.83 pp |
| 2017 | 2017-09-30 | −1,383.23% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −95.95% | +196.63 pp |
| Q1 2026 | 2026-03-31 | −226.99% | +499.35 pp |
| Q4 2025 | 2025-12-31 | −298.35% | +261301.65 pp |
| Q3 2025 | 2025-09-30 | −337.93% | +46.14 pp |
| Q2 2025 | 2025-06-30 | −292.58% | +14529.72 pp |
| Q1 2025 | 2025-03-31 | −726.34% | +12769.90 pp |
| Q4 2024 | 2024-12-31 | −261,600.00% | −250190.83 pp |
| Q1 2024 | 2024-03-31 | −384.07% | +13558.97 pp |
| Q1 2021 | 2021-03-31 | −14,822.30% | −2829.71 pp |
| Q2 2020 | 2020-06-30 | −13,496.25% | −2488.85 pp |
| Q1 2020 | 2020-03-31 | −11,409.17% | −9873.68 pp |
| Q4 2019 | 2019-12-31 | −13,943.04% | — |
| Q3 2019 · Sep 30 | 2019-09-30 | −11,992.59% | — |
| Q3 2019 · Jun 30 | 2019-06-30 | −11,007.40% | — |
| Q2 2019 | 2019-03-31 | −1,535.49% | — |
Over the last five reported fiscal years, Autolus Therapeutics's operating margin increased from −1,383.23% to −358.87%, a change of +1024.36 percentage points. The latest reported quarter, Q2 2026, shows −95.95%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics filings at SEC.gov ↗